Reviewing Kazia Therapeutics Limited (KZIA)’s and AMAG Pharmaceuticals Inc. (NASDAQ:AMAG)’s results

We are contrasting Kazia Therapeutics Limited (NASDAQ:KZIA) and AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) on their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kazia Therapeutics Limited N/A 0.00 N/A -0.90 0.00
AMAG Pharmaceuticals Inc. 474.00M 1.14 169.34M -4.73 0.00

In table 1 we can see Kazia Therapeutics Limited and AMAG Pharmaceuticals Inc.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 provides us the net margins, return on equity and return on assets of both companies.

Net Margins Return on Equity Return on Assets
Kazia Therapeutics Limited 0.00% -23.7% -16.4%
AMAG Pharmaceuticals Inc. -35.73% -5.3% -2.4%

Volatility & Risk

Kazia Therapeutics Limited has a beta of 1.59 and its 59.00% more volatile than S&P 500. In other hand, AMAG Pharmaceuticals Inc. has beta of 0.23 which is 77.00% less volatile than S&P 500.


Kazia Therapeutics Limited’s Current Ratio is 2.4 while its Quick Ratio is 2.4. On the competitive side is, AMAG Pharmaceuticals Inc. which has a 2.9 Current Ratio and a 2.7 Quick Ratio. AMAG Pharmaceuticals Inc. is better positioned to pay off short and long-term obligations compared to Kazia Therapeutics Limited.

Analyst Recommendations

The next table highlights the given recommendations and ratings for Kazia Therapeutics Limited and AMAG Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Kazia Therapeutics Limited 0 0 0 0.00
AMAG Pharmaceuticals Inc. 1 0 0 1.00

Competitively the average target price of AMAG Pharmaceuticals Inc. is $18, which is potential 14.87% upside.

Institutional and Insider Ownership

Kazia Therapeutics Limited and AMAG Pharmaceuticals Inc. has shares held by institutional investors as follows: 2.6% and 0%. Insiders held 28.8% of Kazia Therapeutics Limited shares. Comparatively, AMAG Pharmaceuticals Inc. has 1.8% of it’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Kazia Therapeutics Limited -1.21% -9.19% -22.98% -45.92% -21.17% -15.47%
AMAG Pharmaceuticals Inc. -1.22% -4.45% -26.78% -26.02% 26.45% 34.57%

For the past year Kazia Therapeutics Limited had bearish trend while AMAG Pharmaceuticals Inc. had bullish trend.


On 7 of the 10 factors AMAG Pharmaceuticals Inc. beats Kazia Therapeutics Limited.

Kazia Therapeutics Limited, a biotechnology company, develops anti-cancer drugs. It has three technologies, which include phosphoinositide 3-kinase inhibitors, superbenzopyran, and anti-tropomyosin. The company is developing GDC-0084, a novel targeted therapy that has completed Phase I clinical trial for the treatment of glioblastoma; Cantrixil, which is in Phase I clinical trials to treat ovarian cancer; and Trilexium, a novel therapy that is in early stage pre-clinical development for the treatment of various cancer types. It has collaboration agreement with The University of York, The Children's Cancer Institute Australia, The Mater Institute in Queensland, and the University of Boston. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for womenÂ’s health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families. In addition, it has a option agreement with Velo to acquire the rights to digoxin immune fab, a polyclonal antibody in clinical development for the treatment of severe preeclampsia in pregnant women. The company sells Feraheme to authorized wholesalers and specialty distributors. It has a license agreement with Palatin Technologies, Inc. to research, develop, and commercialize Rekynda, an investigational product designed to be an on-demand treatment for hypoactive sexual desire disorder in pre-menopausal women, as well as with Endoceutics, Inc. to develop and commercialize pharmaceutical products with dehydroepiandrosterone; and development and license agreement with Antares Pharma, Inc. to develop, use, sell, and offer for sale and import and export the Makena auto-injector. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.